Murine monoclonal antibodies (mAbs) are widely used but have limitations if administered in humans. The use of chimeric or humanized mAbs can reduce immunogenicity. The first step in producing such mAbs is to clone murine variable genes from a hybridoma, but it is possible to amplify both functional and aberrant variable genes, as they coexist in the hybridoma. During the development of a murine-human chimeric antibody, we have cloned from a hybridoma the functional heavy chain variable region (V H ) and light chain variable region (V L ) genes of a mAb that blocks the binding of anthrax lethal factor to protective antigen. In this study, we report the detection of two aberrant transcripts from a hybridoma produced using myeloma cell line OUR-1, the development of a method to distinguish between the functional and abundant aberrant V L transcripts, and the origins of these aberrant genes. The aberrant V L gene is derived from OUR-1 cells, while the aberrant V H gene might derive from antibody repertoires in B cells or from gene rearrangement in the hybridoma cells. The aberrant V H and V L genes in this study may facilitate discrimination between the functional and aberrant variable genes from hybridoma cells.
INTRODUCTION
Hybridoma technology is widely used to produce monoclonal antibodies (mAbs) by fusion of murine B cells and myeloma cells. The medical applications of mAbs are numerous in both fundamental research and clinical diagnosis.
1 Murine mAbs administered into the human body may result in an immune response to the foreign immunoglobulin epitopes, mainly because of the development of a human anti-mouse antibody response. 2 Therefore, it is necessary to develop mAbs with low immunogenicity. There are some solutions to this problem, such as generating chimeric, humanized or human mAbs. 3 Murine mAbs have been modified by genetic engineering into chimeric or humanized antibodies, which have a high proportion of human components and the original target specificity of the murine precursors. 4 Furthermore, human mAbs without murine components have been raised by other approaches including phage display, transgenic mice and human-human hybridomas. 5 The first step in generating a chimeric or humanized mAb is to clone the murine variable genes from hybridoma cells. This is complicated if there are any aberrant variable genes similar to the functional ones in the cells. It has been reported that the myeloma cell line P3-X63-Ag8 (derived from clone MOPC21 and used in early hybridoma technology) secretes immunoglobulin, while its sublines, such as Sp2/0, NS-0, OUR-1 and P3-X63-Ag8.653, are considered non-immunoglobulin-secreting fusion partners. 6 It is well known that most myeloma fusion partners still contain a large amount of aberrant kappa chain transcripts with a frame shift at the beginning of the joining region. This transcript cannot be translated into a fully functional immunoglobulin due to a non-functional rearrangement, resulting in a premature termination codon. 7 Several strategies have been applied to overcome the problem of aberrant light chain variable region (V L ) gene. First, if the light chain peptide was sequenced before the gene-specific primers were designed, the aberrant gene would not be amplified at all. 8 Second, Nicholls et al.
9 generated single-chain variable fragment clones by expression in a rabbit reticulocyte lysate-based, coupled transcription-translation system in vitro, and distinguished between the functional and aberrant V L genes on the basis of the sizes of the proteins produced. Third, a peptide nucleic acid clamp specific for the aberrant V L gene during reverse transcription PCR was applied to suppress the amplification of the aberrant one. 10 Lastly, enzymes have been used to treat the aberrant mRNA or DNA: an antisense-directed RNase H digesting the aberrant V L mRNA was used when antibody variable genes were cloned from a hybridoma; 11 a ribozyme specific for the aberrant V L gene was developed and packaged in a retroviral expression vector system to eliminate the endogenous aberrant V L mRNA; 12 several restriction endonucleases cutting the aberrant V L products rather than the functional ones were applied after PCR amplification of the antibody variable genes.
In contrast to the aberrant V L transcript, aberrant heavy chain variable region (V H ) genes are less often reported but are more diverse and complicated, because more than one V H aberrant transcript may exist in a single hybridoma.
14 Furthermore, some aberrant V H genes have no stop codon in the reading frame of V H , which may easily be confused with the functional genes. 15, 16 For these reasons, it is hard to discriminate between the functional and non-functional V H genes, and much more difficult to avoid cloning the aberrant ones before the functional sequences are clarified. Two solutions have been proposed for this problem. One is to use phage display technology and selective panning against the antigen to enrich the functional singlechain variable fragment clones, 17 but it is laborious with low efficiency. The other uses multiplex PCR screening and specific primers for the aberrant CDR3 to isolate the aberrant V H gene, but this may not work if the aberrant sequences still remain unknown. 18 In fact, because of the diversity and unpredictability of the aberrant V H genes, those two methods are not effective and rarely used.
In this study, during the development of a murine-human chimeric antibody, the functional V H and V L genes were cloned from the hybridoma produced using the myeloma cell line OUR-1, and two aberrant V H and V L transcripts were also found. Repeated use of restriction endonuclease BciVI on PCR product and then again on TA plasmids was developed to distinguish between the functional and abundant aberrant V L transcripts. The origins of these two aberrant genes were identified. The aberrant V L gene was confirmed as arising from OUR-1 cells, while the aberrant V H gene may derive from antibody repertoires in the B cells or from gene rearrangement in the hybridoma cells. The method used to identify the aberrant genes may facilitate the cloning of functional antibody variable genes and avoid the amplification of aberrant ones.
MATERIALS AND METHODS

Cell lines
The murine myeloma cell lines Sp2/0 and OUR-1 were maintained in our lab. A murine hybridoma cell line secreting antibody against anthrax lethal factor (named LF8) was developed by fusion of B cells and OUR-1 cells, as described previously.
19 Sp2/0, OUR-1 and LF8 cells were all cultured in OPTI-MEM I supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA). The cells were maintained at 37 uC in a humidified 5% CO 2 incubator.
RNA isolation and cDNA synthesis Total RNA was isolated from LF8 cells by TRIzol reagent (Invitrogen), and cDNA was synthesized using SuperScript II Reverse Transcriptase (Invitrogen) according to the manufacturer's protocols. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was amplified as an internal control (59-ATGGTGAAGGTCGGTGT-39 and 59-TTCACACCCATCA-CAAAC-39). The cDNAs from myeloma cell lines OUR-1 and Sp2/0 were obtained as well.
PCR amplification of V H and V L genes from framework region (FR) 1 to FR4 The murine V H and V L genes were amplified from LF8 cDNA by two approaches. The first primer sets and conditions (described by AndrisWidhopf et al. 20 ) were used to amplify fragments from FR1 to FR 4. An unequal mixture of 19 primers served as the V H sense primer and an equal mixture of four primers as the antisense one. For V L amplification, 17 and 3 primers were used as sense and antisense primers, respectively. PCR reactions were performed in a volume of 100 ml with 2 ml cDNA and 1 ml Taq DNA polymerase (Invitrogen). PCR was carried out for 30 cycles in a PTC-200 thermal cycler (MJ Research, Watertown, MA, USA) with 30 s denaturing (94 uC), 30 s annealing (56 uC), 1 min extension (72 uC) and a final extension of 10 min (72 uC). The sizes of the PCR products were verified by gel electrophoresis in a 1% Tris-acetate-EDTA agarose gel stained with ethidium bromide.
The PCR product of V H was directly TA cloned by ligation of purified PCR product with a pGEM-T Easy vector (Promega, Madison, WI, USA). For V L , the aberrant gene has a BciVI site while the functional one does not. Therefore, the PCR product of V L was digested at 37 uC overnight by the restriction endonuclease BciVI (New England Biolabs, Ipswich, MA, USA) and only non-cut fragments were gel extracted prior to ligation to a pGEM-T Easy vector. TA plasmids containing V L were verified by digestion again with BciVI before sequencing. As there are two BciVI sites in the pGEM-T Easy vector, the TA plasmids inserted with functional V L would be cut into two fragments, whereas the TA plasmids containing aberrant V L would be cut into three.
PCR amplification of V H and V L genes from signal sequence to FR4
The second primer sets and conditions (according to Coloma et al.
21
) were used to amplify the fragments from the signal sequence to FR4. Three V H sense primers (named MHALT1 to MHALT3) were mixed equally or applied individually with the same V H antisense primer. Correspondingly, five V L sense primers (named MLALT1 to MLALT5) were mixed equally or applied individually with the same V L antisense primer. PCR was carried out for 30 cycles with annealing at 60 uC. Purified PCR products were cloned into a pGEM-T Easy Vector directly as mentioned above.
Sequence analysis TA plasmids containing inserted murine V H and V L genes were sequenced using an ABI 3700-capillary electrophoresis DNA sequencer (Applied Biosystems, Foster City, CA, USA). The sequences were assembled and assessed for functional translation using DNAMAN software (version 4.0; Lynnon Corporation, Pointe-Claire, Que., Canada) and were analyzed in VBASE2 database (http://www.vbase2. org) and GenBank database using BLAST (http://blast.ncbi.nlm.nih. gov). Accordingly, aberrant genes with the corresponding sense and antisense primers were identified, as well as the functional genes with the corresponding primers.
Identification of the origins of aberrant variable genes
Aberrant variable gene could arise from an unproductive transcript in myeloma cells, a rearranged transcript in the B cells, or a gene mutation in the fusion process of the two kinds of cells. To identify the origins of the two aberrant genes in this study, variable genes were also amplified using cDNA synthesized from the myeloma cell lines OUR-1 and Sp2/0. According to the sequencing results, sense primers for the functional V H (MHALT1) and the aberrant V H (MHALT3) were used in V H amplification while sense primers for the functional V L (MLALT2) and the aberrant V L (MLALT1) were used in V L amplification. PCR products were sequenced after TA cloning.
RESULTS
Amplification of V H and V L genes from FR1 to FR4
Murine V H and V L genes were amplified using cDNA from LF8 hybridoma cells as the template, and the primer sets and conditions described by Andris-Widhopf et al. GAPDH was amplified as an internal control. Agarose gel electrophoresis demonstrated that the Six TA plasmids containing V H were sequenced and all inserts were the same which had the functional V gene features. For V L , purified PCR product was digested by BciVI to isolate the functional gene. After incubation overnight, most fragments were cut, forming two bands of approximately 180 and 190 bp ( Figure 2 ). Non-cut product was rare. Eight TA plasmids containing V L were digested again by BciVI. Figure 3 shows that only three of eight were cut into two fragments, indicating no cut in V L . Sequencing analysis indicated that those three inserts were the same which had the functional V gene features. The other five plasmids cut into three fragments were sequenced and proven to carry the same aberrant gene.
Amplification of V H and V L genes from signal sequence to FR4
Using the primer sets and conditions according to Coloma et al., the expected PCR products were about 400 bp. As shown in Figure 4 , V H genes were successfully amplified by PCR using the sense primers mixture, MHALT1 and MHALT3 with the antisense primer, respectively. No product was obtained with sense primer MHALT2. The sequencing results identified that MHALT1-amplified V H had the functional V gene features, and that MHALT3-amplified V H was an aberrant one (named abVH-LF8, with Genbank accession no. HM046413). Similarly, V L genes were successfully amplified by PCR using the sense primers mixture, MLALT1 and MLALT2 with the antisense primer. No product was obtained with sense primers MLALT3 to MLALT5 ( Figure 5 ). The sequencing results showed that MLALT2-amplified V L had the functional V gene features, and that MLALT1-amplified V L was an aberrant one (named abVL-LF8) which was identical to the aberrant V L gene amplified from FR1 to FR4, except for an upstream signal sequence.
Sequencing analysis
The V H and V L genes of LF8 with functional V gene features were cloned into eukaryotic vectors to express chimeric immunoglobulin G (IgG) against lethal factor according to the method of RoqueNavarro et al. 22 Chimeric IgG protein expression (both heavy and light chains) was confirmed by ELISA and SDS-polyacrylamide gel electrophoresis. Binding of the chimeric IgG to lethal factor was demonstrated by ELISA and confirmed the preservation of the antigen-binding specificity of the parental antibody LF8 (data not shown). The functional variable genes of LF8 were registered in GenBank with accession nos. GU290193 and GU290194.
According to analysis of the GenBank database using BLAST, the abVL-LF8 gene showed about 97% homology to the well-known MOPC21 V L aberrant gene derived from myeloma cell line P3-X63-Ag8.653 (GenBank accession no. M35669). The abVH-LF8, if truncated the upstream signal sequence, was homologous to several aberrant V H genes released in GenBank: 98 and 96% homology to aberrant V H genes derived from fusion partner P3-X63-Ag8.653 (GenBank accession nos. EU121635 and X58634, respectively); 96% homology to an aberrant V H genes derived from fusion partner P3U1 (GenBank accession no. D50398). The main differences located at 59 and 39 ends, and all genes had no upstream signal sequence reported except the abVH-LF8. Interestingly, the abVH-LF8 had 94% identity to a functional V H gene (GenBank accession no. U60820) with a few different nucleotides, especially an inserted 'A' in CDR3 (at 365 bp in abVH-LF8). The abVH-LF8 had 82% identity to another functional V H gene derived from the hybridoma generated using myeloma cell line Sp2/0 (GenBank accession no. AY646832), with an inserted 'G' (at 363 bp in abVH-LF8) and 21 base pairs deleted in CDR3. The inserted 'A' and 'G' were confirmed by several sequencing results and these two inserts also showed up in all aberrant V H genes listed above. Alignment of the DNA sequences of the abVH-LF8 is shown in Figure 6 with the most homologous aberrant V H gene (GenBank accession no. EU121635) and two functional ones.
Identification of the origins of aberrant variable genes
Variable genes were also amplified using cDNA synthesized from the myeloma cell lines OUR-1 and Sp2/0 to identify the origins of the two aberrant genes in this study. MHALT1 and MHALT3 with corresponding antisense primer were used in V H amplification. MLALT1 and MLALT2 with corresponding antisense primer were used in V L amplification. As shown in Figure 7 , the functional V H and V L genes were only in the LF8 cells, while the aberrant V L genes were in OUR-1, LF8 and Sp2/0 cells. According to sequencing results, the aberrant V L genes in OUR-1 and Sp2/0 were identical to abVL-LF8 in LF8 cells. However, abVH-LF8 was only found in LF8 cells, not OUR-1 or Sp2/0 cells.
DISCUSSION
Today, fully human antibodies are desired for application in humans. However, there are difficulties, because it is generally not ethical to immunize humans with antigen in order to produce a human antibody. In addition, the lack of a human cell line that has high fusion efficiency and that does not secret immunoglobulin has hindered the Figure 6 Alignment of the DNA sequences of abVH-LF8 (HM046413) with other V H genes. The DNA sequence of aberrant abVH-LF8 was aligned with an aberrant V H gene (EU121635) and two functional V H genes (U60820 and AY646832). Signal sequences are underlined and complementarity-determining regions of functional genes are shadowed. Gaps are represented by dashes, identical bases by *. 23 Consequently, production of a chimeric mAb and a humanized mAb are often carried out. 24 The first step in creating these antibodies is to clone the functional immunoglobulin variable genes by PCR amplification from the cDNA of a hybridoma. The major problem in rapidly obtaining heavy and light chain variable genes from a hybridoma is the occurrence of aberrant mRNAs that can be transcribed but that have no function. 25 If the aberrant gene is used in the construction of the chimeric or humanized antibody, it may produce immunoglobulin that has low affinity for the antigen and is completely non-functional. Several strategies may decrease the amplification of aberrant variable genes, but they have limitations primarily because the aberrant genes may be highly homologous to the functional ones. 26 As a result, the more information we have about the aberrant genes, the higher efficiency of functional gene amplification we can obtain and the better we can avoid the aberrant genes in antibody engineering.
Identification of two aberrant transcripts
An antibody repertoire is generated from a large number of antibody genes. Gene rearrangements lead to antibody diversity. 27 Primer design is very important for the amplification of variable genes. The sense primer can be set to pair with either FR1 or the upstream signal sequence, while the antisense primer pairs with either FR4 or the beginning of the constant region. As the signal sequence and the constant region are usually conserved in the immunoglobulin genes, few primers paired to those regions might be required. 28 Although these primer sets have proven to be successful and are used widely in antibody variable gene extraction, the aberrant genes can also be amplified. In this study, four primer sets were used for immunoglobulin variable gene cloning. For amplification from FR1 to FR4, 19 primers were used for V H sense and 4 primers for antisense (as described by Andris-Widhopf et al.). For V L , 17 and 3 primers were used for sense and antisense, respectively. It would be laborious to use these primers individually to distinguish the functional genes from aberrant ones, so other measures are needed to reduce aberrant amplification. For amplification from the conserved signal sequence to FR4, as reported by Coloma et al., only three primers were used for V H sense and five for V L sense, with only one antisense primer for V H and one for V L . Accordingly, the sense primers could be applied individually with an antisense primer to isolate the functional and aberrant genes.
Because amplification of an aberrant V L gene from the cDNA of a hybridoma is very common, two methods were employed to reduce aberrant amplification from the MOPC21k allele. In one approach, the PCR product of V L was digested by BciVI to cut the aberrant gene and isolate the functional gene. Most fragments were cut, and an uncut band was hardly seen, suggesting that the aberrant gene has much greater abundance than the functional one. A second digestion of TA plasmids was used to verify functional gene isolation. To our surprise, only three out of eight plasmids contained a functional gene, resulting from the relative low efficiency of the first digestion by BciVI, which is not accordant with the results of Juste et al. As far as we are concerned, it is necessary to do the second digestion.
In the other approach, five sense primers were used individually to amplify from the V L signal sequence. The sequencing results of the amplification products were then analyzed in the VBASE2 database to distinguish the functional from aberrant V L genes. In our results, it was shown that the functional and the aberrant V L genes were amplified by two separate sense primers: MLALT2-amplified V L gave the functional gene, while MLALT1-amplified V L gave the aberrant one. If the functional V L had shared the same sense primer with the aberrant V L , further steps would have been required for identification. According to analysis in the GenBank database using BLAST, the abVL-LF8 showed about 97% homology to the well-known MOPC21 V L aberrant gene derived from the myeloma cell line P3-X63-Ag8.653; only a few nucleotides located in primer regions are different. This indicates that there might be only one V L aberrant gene existing in several myeloma cell lines, and the sequences reported are essentially identical.
For amplification of the V H genes, there was no difficulty in using the primer set described by Andris-Widhopf et al. Six TA plasmids containing V H were identified to be inserted with the same functional gene, and no aberrant V H gene was found. While using the primer set described by Coloma et al., two transcripts were found with different sense primers. Sequencing showed that MHALT1-amplified V H had the functional V gene features while MHALT3-amplified V H was an aberrant one. This unexpected abVH-LF8 showed high homology to both aberrant genes and functional ones, according to the GenBank database. The results confirm the homology of P3-X63-Ag8.653 and OUR-1, an ouabain-resistant subclone of the former, 29 and verify that some aberrant V H genes have high homology to the functional ones. It could be confusing to distinguish functional V H genes from aberrant ones. The results also suggest that abVH-LF8 may be a mutation and rearrangement of a functional transcript existing in the B-cell genome.
The aberrant variable gene may arise from an unproductive transcript in myeloma cells, a rearranged transcript in B cells, or a gene mutation in a fusion of the two kinds of cells. 30 To identify the origins of the two aberrant genes, variable genes were also amplified using cDNA synthesized from myeloma cell line OUR-1. Sp2/0 myeloma cells were also used because abVH-LF8 showed high homology to a functional V H gene derived from the hybridoma generated using Sp2/0. The two fusion partners, OUR-1 and Sp2/0, do not secrete immunoglobulin but have the same abVL-LF8 as LF8 does. However, abVH-LF8 was only amplified in LF8 cells, not in OUR-1 or in Sp2/0 cells, which indicates that the abVH-LF8 might originate from the antibody repertoire in B cells or from gene rearrangement in the hybridoma cells.
In conclusion, we have identified two aberrant variable genes when cloning functional genes to develop a murine-human chimeric antibody. The abVL-LF8 reported here in LF8, OUR-1 and Sp2/0 is identical to the MOPC21 V L aberrant gene, and the origin of this aberrant V L gene is also confirmed to be accordant with the known research results. Further, digestion twice by BciVI can reduce the chance of TA cloning of the aberrant V L gene and effectively isolate the functional one. Although aberrant V L gene has high abundance, there might be only one V L aberrant gene existing in several myeloma cell lines and many methods have been proposed to avoid it. On the contrary, the aberrant V H genes have seldom been reported; they are more complicated and diverse than the aberrant V L gene. There is no better strategy than sequencing and analysis in databases to avoid the aberrant V H genes. The abVH-LF8 reported in this study may facilitate discrimination between the functional and aberrant V H genes from hybridoma cells, especially those developed using OUR-1 cells as a fusion partner.
